a-Tocopheryl succinate (a-TOS) is a selective inducer of apoptosis in cancer cells, which involves the accumulation of reactive oxygen species (ROS). The molecular target of a-TOS has not been identified. Here, we show that a-TOS inhibits succinate dehydrogenase (SDH) activity of complex II (CII) by interacting with the proximal and distal ubiquinone (UbQ)-binding site (Q P and Q D , respectively). This is based on biochemical analyses and molecular modelling, revealing similar or stronger interaction energy of a-TOS compared to that of UbQ for the Q P and Q D sites, respectively. CybL-mutant cells with dysfunctional CII failed to accumulate ROS and underwent apoptosis in the presence of a-TOS. Similar resistance was observed when CybL was knocked down with siRNA. Reconstitution of functional CII rendered CybL-mutant cells susceptible to a-TOS. We propose that a-TOS displaces UbQ in CII causing electrons generated by SDH to recombine with molecular oxygen to yield ROS. Our data highlight CII, a known tumour suppressor, as a novel target for cancer therapy.
Introduction
Cytotoxic drugs acting by selectively affecting mitochondria in cancer cells, 'mitocans' (Neuzil et al., 2006 (Neuzil et al., , 2007 Ralph et al., 2007) , are attractive for the treatment of cancer (Ko et al., 2004; Bonnet et al., 2007; Dong et al., 2007; Neuzil et al., 2007) . Prime examples of such drugs are a-tocopheryl succinate (a-TOS) (Neuzil et al., 2001a, b) , 3-bromopyruvate (3BP) (Geschwind et al., 2002; Ko et al., 2004) and dichloroacetate (DCA) (Bonnet et al., 2007) . 3BP inhibits the glycolytic pathway enzyme hexokinase, and succinate dehydrogenase (SDH), suppressing adenosine 5'-triphosphate production and mitochondrial respiration (Ko et al., 2001; Xu et al., 2005) . DCA targets cancer cells by inhibiting pyruvate dehydrogenase kinase (Bonnet et al., 2007) . Finally, b-phenylethyl isothiocyanate selectively kills cancer cells by eliciting the generation of reactive oxygen species (ROS) (Trachootham et al., 2006) . a-TOS, a redox-silent analogue of vitamin E (VE), causes rapid production of ROS in cancer cells, triggering apoptosis (Weber et al., 2003; Stapelberg et al., 2005; Swettenham et al., 2005; Wang et al., 2005) . a-TOS also inhibits the anti-apoptotic function of Bcl-2 and Bcl-x L by blocking their BH3 domains (Shiau et al., 2006) . This may explain, in part, how a-TOS sensitizes cancer cells to other anti-cancer drugs. However, it does not explain how the agent causes accumulation of ROS, obligatory mediators of a-TOS-induced apoptosis. Antioxidants like superoxide dismutase (SOD) or the mitochondrially targeted coenzyme Q (MitoQ) (James et al., 2005 (James et al., , 2007 negate the apoptotic action of a-TOS (Alleva et al., 2001; Weber et al., 2003; Stapelberg et al., 2005) . Cancer cells that accumulate low levels of ROS in response to a-TOS are less susceptible to apoptosis (Kogure et al., 2002; Kang et al., 2004; Stapelberg et al., 2005; Swettenham et al., 2005) .
The effects of a-TOS on cancer cells, combined with a reduced toxicity towards normal cells, result from a greater antioxidant defence of the latter (Church et al., 1993; Safford et al., 1994; Allen and Balin, 2003; Huang et al., 2006) and/or increased levels of esterases that hydrolyse the pro-oxidant a-TOS by hydrolysis to the redox-active, non-apoptogenic a-TOH Neuzil and Massa, 2005) .
The molecular target of a-TOS in cancer cells that results in ROS production has not previously been defined. One possibility how the VE analogue could give rise to ROS and ensuing apoptosis is by interfering with the ROS-generating centres along the mitochondrial electron redox chain. Of particular interest is complex II (CII), since previous data showed that toxicity of a-TOS on cancer cells can be suppressed by MitoQ (Stapelberg et al., 2005; Swettenham et al., 2005) that is known to interact with the ubiquinone (UbQ)-binding sites of CII (James et al., 2005 (James et al., , 2007 . Here, we examined the effect of a-TOS on the respiratory chain, identifying the UbQbinding pockets in CII as the key molecular target for the agent, and propose that its interaction with the UbQ-binding sites results in ROS generation. The UbQbinding sites of CII represent a novel, and thus far unrecognized target for anti-cancer drugs.
Results
Cancer cells accumulate ROS and undergo apoptosis when exposed to a-TOS We first tested if exposure of breast cancer cells to a-TOS caused generation of ROS. The results obtained by flow cytometry (Figures 1a, b) show that both erbB2-low MCF7 and erbB2-high MDA-MB-453 cells accumulated ROS and underwent apoptosis when challenged with a-TOS. Electron paramagnetic resonance (EPR) spectroscopy confirmed ROS generation occurring in cells exposed to a-TOS (Figures 1c and d) . ErbB2-low MCF7 and -high MDA-MB-453 cells were exposed to a-TOS at 50 mM and for times shown, and assessed for dihydroethidium (DHE)-(a) and annexin V-positive cells (%) (b). Jurkat cells were treated with 50 mM a-TOS for 2 h or as shown and assessed for ROS accumulation using electron paramagnetic resonance (EPR) spectroscopy (c, evaluation of the 5,5-dimethyl-1-pyrroline N-oxide (DMPO)-OH adduct level in nmol/mg protein; d, representative EPR spectra of cells exposed to a-TOS in the absence (1) or presence of mitochondrially targeted coenzyme Q (MitoQ) (2) or to MitoQ only (3)). (e) The kinetics of apoptosis induction in Jurkat cells exposed to 50 mM a-TOS in the absence or presence of MitoQ. Control (C) MCF7 parental and r 0 cells exposed to 50 mM a-TOS for 2 h (T) were assessed for ROS accumulation (f) and apoptosis (g). Where indicated, the cells were pretreated for 1 h with 2 mM MitoQ (MQ) or co-treated with SOD (polyethylene glycol (PEG)-SOD, 750 U/mg). The data shown represent mean values ± s.d. (n ¼ 3). The symbol '*' denotes significant difference (Po0.05) in the level of apoptosis and ROS of treated cells compared with the untreated control cell population. cells with dysfunctional electron redox chain, when exposed to a-TOS, showed relatively low levels of ROS accumulation and the induction of apoptosis was reduced (Figures 1f and g ).
a-TOS targets the UbQ-binding pockets on CII Studies with a-tocopherol (a-TOH) indicated that it could bind to the UbQ site in CII where it acts as a competitive inhibitor of SDH (Yu and Yu, 1983) . We thus investigated whether a-TOS, with its related structure but opposing biological activity, interferes with UbQ binding to CII. Using high levels of succinate (20 mM) that is capable of entering cells (Spencer, 1977; Maehara et al., 1988) to promote both SDH activity (Maehara et al., 1988; Berridge and Tan, 1993) and mitochondrial respiration proceeding via CII, NeuTL cells were assayed for SDH activity in the presence or absence of a-TOS. The inhibitors of SDH activity, 3BP (Sanborn et al., 1971 ) and 3-nitropropionic acid (3NPA) (Scallet et al., 2003) , were employed as positive controls. To establish the relationship between inhibition of SDH and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction, initial experiments with 3BP and 3NPA were performed in the absence of succinate that might otherwise compete for binding to the enzyme, and the results confirmed that 3BP and 3NPA inhibited CII-mediated MTT reduction and that SDH activity and MTT reduction were closely related ( Figure 2a) . Thenoyltrifluoroacetone (TTFA) is an inhibitor of CII that blocks the succinate-dependent MTT reduction by targeting the UbQ-binding sites rather than the SDH enzyme catalytic site (Sun et al., 2005) . The CII UbQ sites are situated beneath the active site of SDH, in the transmembrane region of the CII. With high succinate levels as the substrate driving CII-mediated MTT reduction in whole cells, treatment with 3BP, a-TOS or TTFA inhibited MTT reduction in a dose-dependent manner (Figures 2b-d) . Pre-incubation of cells with MitoQ , a form of UbQ that preferentially localizes to mitochondria where it binds to CII but not CIII (Kelso et al., 2001; James et al., 2005 James et al., , 2007 , overcame the inhibition in MTT reduction by TTFA and a-TOS, but not by 3BP (Figures 2b-d) . These results indicate that a-TOS inhibits SDH activity in a similar manner to TTFA.
Verification that a-TOS inhibits mitochondrial respiratory CII activity Additional support for the role of a-TOS in inhibiting CII activity was obtained with mitochondrial preparations from rat liver and membrane fractions from Paracoccus denitrificans. SDH activity decreased rapidly after treatment with a-TOS (Figure 3 ). These data Complex II as an anti-cancer drug target L-F Dong et al strongly indicate that a-TOS, acting directly on the UbQ site(s) of CII, interferes with the electron flow to phenazine methosulphate (PMS) and 2,6-dichlorophenol-indophenol (DCPIP). In contrast, a-TOS had no effect on NADH dehydrogenase (CI) activity (data not shown), consistent with selective targeting of CII. Next, we tested whether a-TOS initiated apoptosis in parental Chinese hamster lung fibroblasts (B1 cells), CIdysfunctional cells (B10 cells) and CII-dysfunctional cells (B9 cells, with a mutation in the gene encoding the succinyl dehydrogenase subunit C (SDHC subunit, CybL)). B9 cells were less responsive to a-TOS, with lower levels of ROS accumulation ( Figure 4a (Figure 4g ). The siRNA approach was specific for SDHC, since we did not observe any changes in the level of the SDHB subunit protein in the SDHC-treated MCF7 cells (data not shown).
Molecular modelling reveals strong binding of a-TOS
to UbQ sites on CII To rationalize our results, suggesting that a-TOS interacts with CII via the UbQ-binding sites, we performed molecular modelling using AutoDock (Morris et al., 1998). The crystal structure of porcine heart mitochondrial CII has been reported (Sun et al., 2005) . Since it exhibits high sequence identity with human CII (95-97% for the individual subunits), we used this structure (1ZOY) and the related structure (1ZP0) with the inhibitor TTFA bound as the basis for our study. Structural analysis revealed the proximal UbQ-binding site (Q P ) and also identified the position of the proposed distal UbQ-binding site (Q D ). To test the feasibility of using AutoDock for this system, we first simulated the binding of UbQ5 to both the Q P and the proposed Q D Complex II as an anti-cancer drug target L-F Dong et al sites. UbQ5 was chosen as it is of similar size to a-TOS ( Figure 5e ) and contains a similar number of rotatable bonds (16 and 17, respectively). Figure 5a indicates that UbQ5 docked in Q P to a deeper position than that observed for the portion of UbQ resolved in the published crystal structure (Sun et al., 2005) . UbQ5 was also found to dock into the proposed Q D site, with the UbQ ring positioned in front of the binding site and the hydrophobic tail located inside the site (Figure 5c ). In the Q P site, the ring system of a-TOS sits in the same binding pocket as the UbQ ring but is tilted to one side. The succinate ester moiety extended deeper into the binding site protruding down towards the location of the prosthetic haem group. The carboxyl group fits neatly into this pocket and is involved in a bidentate hydrogen bond with Ser42(C) (Figure 5b ). Ser42(C) also interacts with the ester oxygen of a-TOS. As befits the hydrophobic nature of the remainder of the a-TOS molecule, all the other interactions with the protein are hydrophobic. Thus, the hydrocarbon side chain loops around and extends out of the Q P site and along the same channel where the isoprenoid side chain of UbQ5 is located.
In the Q D site, the phenyl ring system of a-TOS sits towards the bottom of the binding site with the succinate ester moiety extending out the bottom of the site in a similar way to that observed for the head group of the phospholipid visible in the original crystal structure (Figure 5c ). The succinate moiety hydrogen bonds to Lys135(D) and Lys128(D) (Figure 5d ), while the hydrocarbon side chain loops around the inside of the binding site. The calculated energy of interaction for the docked conformations of a-TOS (Figure 5e ) suggested that it can bind at either site. While the binding energy of a-TOS at the Q P site is slightly less than that of UbQ5, a-TOS would certainly compete with UbQ5. At the Q D site, a-TOS shows a much stronger binding energy than that of UbQ5 and would be expected to easily displace it from this site ( Figure 5e ).
We had to use UbQ5 in the modelling study because of the relatively high number of rotatable bonds in a-TOS (17) and UbQ5 (16); adding the full isoprene tail of UbQ10 (with the extra rotatable bonds) makes the AutoDock calculations intractable. Also, data analysis from the published crystal structure only shows electron density for the very start of the isoprenoid chain suggesting that the rest of the tail is not particularly tightly bound at this site (Sun et al., 2005) . Therefore, the expected interaction energies of UbQ10 for the two sites will be similar to those calculated for UbQ5.
Apoptosis induced by a-TOS is independent of its BH3 mimetic activity Shiau et al. (2006) reported that VE analogues possess BH3 mimetic activity, interacting with Bcl-2 and Bcl-x L . To ascertain whether the apoptogenic activity of a-TOS is dependent on this activity, we utilized the BH3 mimetic BH3I-2 0 (Calbiochem, Gibbstown, NJ, USA) (Degterev et al., 2001; Milanesi et al., 2006) . Cytotoxicity of a-TOS was assessed in MCF7 cells exposed to increasing concentrations of BH3I-2 0 . We found that levels >5 mM caused mitochondrial destabilization (not shown). Combining BH3I-2 0 (5 mM) with a-TOS significantly enhanced the sensitivity of the cells to the VE analogue (Figure 6 ). These data indicate a synergistic effect of BH3I-2 0 and a-TOS, and suggest that the VE analogue induces apoptosis predominantly by other modes than acting as a BH3 mimetic.
a-TOS inhibits tumour growth irrespective of erbB2 status
To demonstrate anti-cancer activity of a-TOS, we first determined whether the VE analogue could suppress tumour growth in an animal model of breast cancer with low erbB2 expression, given that over two-thirds of human breast cancers express low levels of the receptor tyrosine kinase (Slamon et al., 1989) . Nude mice were xenotransplanted with MCF7 cells and treated with a-TOS. Data in Figure 7a show that a-TOS repressed tumour growth with a significant decrease in the tumour size. We then tested treatment of erbB2-high breast carcinomas using the transgenic FVB/N c-neu mice (Guy et al., 1992) . Compared to the controls, the tumours in the a-TOS-treated mice showed a 30-40% reduction in size over the several weeks of treatment. These results suggest a high level of efficacy for a-TOS therapy against breast carcinomas regardless of their erbB-2/ HER2 status.
Discussion
It is increasingly recognized that mitochondria are emerging as effective targets that may provide the selectivity needed for potent anti-cancer therapy (Neuzil et al., 2001b; Don and Hogg, 2004) . Studies with mitocans have shown exciting potential for cancer therapy since these drugs have limited side effects, and some of these compounds possess specificity for cancer cells (Neuzil et al., 2007) .
This study supports a role for a-TOS as a competitive inhibitor of the UbQ site(s) in CII. Our data reveal that both the Q P and Q D sites of CII are targets for a-TOS. Binding of the VE analogue at CII promotes ROS generation in cancer cells. The validity of the molecular modelling approach is supported by our identification of several other compounds with strong interaction energies for the CII UbQ site(s) (not shown). Of them, pyridoxal phosphate has been previously identified as a potent inhibitor of SDH activity by competing with UbQ (Choudhry et al., 1985 (Choudhry et al., , 1986 .
Molecular modelling strongly supports the notion that the binding of a-TOS to CII within the Q P and Q D sites is a key to the apoptogenic activity of the agent. These observations were verified by experiments with cells where a mutation in CybL disrupts the CII function and the ability of cells to survive when growing in the presence of succinate. First, CybL-mutant cells, unlike their CI-deficient and parental counterparts, failed to accumulate ROS and induce apoptosis when exposed to a-TOS, while reconstitution of functional CII reinstated susceptibility to the agent. These findings can be reconciled with a study reporting resistance of CybLmutant cells to apoptosis when challenged with various cytotoxic agents (Albayrak et al., 2003) . Hence, CII is an important driver of ROS production mediated by cytotoxic drugs. Second, we demonstrate that knocking-down CybL rendered cancer cells resistant to a-TOS-triggered ROS accumulation and apoptosis induction (Figure 4 ). This is important evidence, since the siRNA approach is an acute insult to the cells, while a knockout cell line can undergo adaptive differential expression of genes, potentially obscuring the direct effect of the knockout genotype. (Hartshorn, 2002) , while those in (b) and (d) were prepared using Ligplot (Wallace et al., 1995) .
Complex II as an anti-cancer drug target L-F Dong et al
We and others have previously shown a-TOS to be a potent inducer of ROS in cancer cells (Weber et al., 2003; Kang et al., 2004) . The a-TOS drug target we have identified as CII of the respiratory chain has been proposed as a contributor to cellular ROS production (McLennan and Degli-Esposti, 2000) . Addition of MitoQ to cells did not overcome the 3BP-mediated inhibition of SDH activity since 3BP acts upstream at the site of the SDH catalytic centre. MitoQ overcame both the TTFAand a-TOS-mediated inhibition of SDH activity. While TTFA binds to both Q P and Q D sites in CII (Sun et al., 2005) like a-TOS, it displays less selective toxicity ) than the VE analogue for killing cancer cells (Neuzil et al., 2001b) . Further studies are required to understand this differential specificity.
When a-TOS displaces UbQ from its binding site(s) on CII, electrons may no longer be tunnelled down the SDH hydrophilic head on to AD and relayed via the [Fe-S] centres and the haem group to UbQ (Cheng et al., 2006; Tran et al., 2006) . Instead, they recombine with molecular oxygen to enhance superoxide anion radical (O 2 À ) production that leads to induction of apoptosis in the cancer cell. Although it is possible that ROS generation occurs via the FAD site (Yankovskaya et al., 2003; Gottlieb and Tomlinson, 2005) , it cannot be excluded that electrons in the case of a dysfunctional CII, interact with oxygen, which is dissolved in the membrane part of CII (Slane et al., 2006) . Another possibility is that electrons move to CI by reverse electron transport, where they form O 2 À (Adam-Vizi and Chinopoulos, 2006) . Blocking UbQ binding promotes ROS generation by removing the opportunity of electrons to react with its acceptor (Figure 8 ). This is strongly supported by studies with the Caenorhabditis elegans mev-1 mutant that can oxidize succinate to Figure 6 a-Tocopheryl succinate (a-TOS) causes apoptosis independent of its BH3 mimetic activity. MCF7 cells were treated with 5 mM BH3I-2 0 or exposed to 30 mM a-TOS following 10 min pre-treatment with 5 mM BH3I-2 0 . Cells were then assessed for mitochondrial depolarization (a), reactive oxygen species ( Figure 7 Inhibition of breast cancer in mouse models by atocopheryl succinate (a-TOS). (a) Nude mice were inoculated with MCF7 cells and once tumours became established, the animals were treated every 3 days with 10 mmol per mouse of a-TOS dissolved in dimethyl sulphoxide (DMSO) or with DMSO alone, by i.p. injection. Tumour size was measured using callipers and was correlated to the size of the carcinomas at the onset of the therapy. Four animals were used in each group. (b) Female FVB/N c-neu mice with small tumours received either 10 mmol a-TOS solubilized in corn oil/4% ethanol (n ¼ 11) or the excipient alone (control, n ¼ 9) by i.p. injection once every 3 days. Tumour size was quantified using ultrasound imaging (USI). Two independent experiments were conducted. The inset in b shows representative images of tumours acquired by USI in the control (upper image) and treated (lower image) FVB/N c-neu mice on day 22 of the experiment. The results shown are mean values±s.e.m. The symbol '*' denotes significant differences (Po0.05).
fumarate but cannot transfer electrons to UbQ, resulting in increased ROS levels and premature ageing (Ishii et al., 1998) . This can be reconciled with a recent study suggesting that the Q P site is important for electron channelling between UbQ and the juxtapositioned haem group , which contributes to stabilization of the transient ubisemiquinone radical (Tran et al., 2006) . Interestingly, several human cancers, such as paragangliomas, resulting from genetic disorders due to mutations in CII subunits, including SDHC, may also be induced by increased ROS formation (Niemann and Muller, 2000; Gottlieb and Tomlinson, 2005; Ishii et al., 2005) .
Our results are not dissimilar to a recent report documenting selective molecular mechanism of apoptosis induction in cancer cells by adaphostin, a compound that binds to the UbQ reduction (Q i ) site of CIII, resulting in ROS accumulation (Le et al., 2007) . That CII is of importance in ROS formation is further evidenced by a recent report showing that non-steroid anti-inflammatory drugs caused ROS generation in cells, of which the majority was derived from CII (Soller et al., 2007) . Moreover, ferulenol, a coumarine derivative, has been reported to affect the succinate UbQ reductase by interfering with the UbQ cycle (Lahouel et al., 2007) . Given these recent results, more drugs affecting CII are likely to be found in near future.
Although anti-cancer drugs have been described that may target the UbQ sites on the oxidoreductase complexes along the mitochondrial respiratory chain to increase cellular ROS levels and activate apoptosis (Dias and Bailly, 2005; Hall, 2005; Le et al., 2007) , a-TOS has an additional feature in that it also disrupts the anti-apoptotic function of Bcl-2 and Bcl-x L by blocking their BH3-binding domain (Shiau et al., 2006) . Hence, a-TOS may prove superior for inducing cancer cell death because of its dual action on two important targets, Q P and Q D sites of CII, and the Bcl-2 family proteins, promoting the induction of mitochondrially mediated apoptosis. This notion is further corroborated by our data revealing sensitization of cancer cells to a-TOS by the BH3 mimetic BH3I-2 0 . We also show that a-TOS suppresses tumour progression in mouse models of breast cancer regardless of their erbB2 status. This could be explained by a-TOS blocking the CII UbQ-binding sites, thereby causing ROS generation with ensuing induction of apoptosis, acting in a dominant manner downstream of any antiapoptotic pro-survival activity resulting from the erbB2 receptor tyrosine kinase signalling. This makes the VE analogue a potentially useful anti-cancer agent when dealing with the challenge of breast cancers with high levels of expression of erbB2/HER2 that are rather recalcitrant to therapy (Slamon et al., 1989) . Similarly, we recently demonstrated that a peptide conjugate of a-TOS (with relatively high affinity for the erbB2 receptor) effectively kills breast cancer cells .
To conclude, we present the molecular targets of the intriguing anti-cancer agent a-TOS with low toxicity to non-cancerous tissues (Weber et al., 2002) , a compound that acts by selectively affecting mitochondria, organelles that are essential both for life and for unleashing the apoptosis machinery (Newmeyer and FergusonMiller, 2003) . We identify the UbQ-binding sites of the mitochondrial CII as a new target for anti-cancer drugs, and propose that these results will not only lead to the establishment of VE analogues as efficient anti-cancer agents but also will increase the interest in mitochondrial components as targets that are yet to be fully exploited for selective cancer therapy. Work is presently underway, using in silico modelling, to identify lead compounds that induce apoptosis by interfering with the UbQ-binding site(s) of CII and develop them into efficient and selective anti-cancer drugs. Our results on the molecular mechanism of apoptosis induced in cancer cells by a-TOS may be reconciled with our clinical outcome from a mesothelioma patient who has been treated with the VE analogue. The data reveals a significant clinical benefit with a-TOS therapy, causing a reduction in tumour volume and improved the well being of our subject who had a lethal type of neoplastic pathology (Robinson et al., 2005) . We are currently preparing to set-up a larger clinical trial in which a cohort of mesothelioma patients will be treated with the mitocan a-TOS.
Materials and methods

Cell culture and treatment
Human breast cancer cells MCF7 with low and MDA-MB-453 with high levels of erbB2, and the murine breast cancer erbB2-high NeuTL cells derived from the c-neu mice were cultured in Dulbecco's modified Eagle's media (DMEM) with 10% fetal calf serum (FCS) and antibiotics. Jurkat T lymphoma cells were cultured in RPMI-1640 medium with 10% FCS and antibiotics. MCF7 cells deficient in mtDNA (r 0 ) were prepared as described (Weber et al., 2003) . CI-dysfunctional (B10 cells) (Seo et al., 1997) , CII-dysfunctional (B9 cells with mutant CybL (Oostveen et al., 1995) ) and the parental Chinese hamster lung fibroblasts (B1 cells) (Oostveen et al., 1995) Figure 8 Model for the interference of a-tocopheryl succinate (a-TOS) with the mitochondrial electron chain. The scheme shows the proposed effects of a-TOS with the branching of the electron transport chain in its upstream region and clarifies the point of inhibition by a-TOS as specifically interacting with complex II (CII). It also suggests CII as the possible site of superoxide generation, although its precise location within succinate dehydrogenase (SDH) has not been identified. The possible reverse electron transport from CII to CI is also shown. grown in DMEM with 10% FCS, antibiotics, 10 mg/ml glucose and non-essential amino acids.
Assessment of apoptosis, ROS accumulation and membrane potential Apoptosis was quantified using the annexin V-FITC kit (PharMingen, Franklin Lake, NJ, USA) (Weber et al., 2003) . Cellular ROS were detected with the probe dihydroethidium (Molecular Probes, Carlsbad, CA, USA) by flow cytometry (Weber et al., 2003) , or by trapping with 5,5-dimethyl-1-pyrroline N-oxide (DMPO; Sigma, St Louis, MO, USA) using EPR spectroscopy (Weber et al., 2003) . Cells were also pre-treated for 1 h with 2 mM MitoQ (James et al., 2005) or co-incubated with SOD (polyethylene glycol-SOD, 750 U/ml; Sigma). The mitochondrial inner transmembrane potential (DC m,i ) was assessed using 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidoazolyl-carbocyanino iodide (JC-1; Molecular Probes) (Weber et al., 2003) .
SDH activity assay MTT solutions were prepared by dissolving 2.5 mg/ml MTT (Sigma) in phosphate-buffered saline (PBS) alone or phenol red-free RPMI media with 20 mM succinic acid, pH 7.4. Solutions of 3NPA, a-TOS and MitoQ in ethanol, TTFA in dimethyl sulphoxide (DMSO) or 3BP in PBS were added to cells simultaneously with MTT. The drugs were tested in exponential growth phase of cells in 96-well plates using 4-8 replicates per dilution. Cells were also pre-incubated for 1 h with 2 or 5 mM MitoQ. Final concentrations of ethanol or DMSO in cultures were p0.1% (v/v). Treated and control cells were exposed to MTT for 2 or 4 h at 37 1C and 5% CO 2 . Supernatants were removed, except for 30 ml, before adding 150 ml DMSO to dissolve the formazan crystals, and absorbance measured at 570 nm.
Preparation of mitochondrial particles
Rat liver mitochondria were freshly prepared as described (Rice and Lindsay, 1997 ) and stored at À20 1C until used. P. denitrificans CCM982 (NCIB 8944) was grown anaerobically at 30 1C in a medium containing 50 mM succinate as the carbon source and 10 mM nitrate as the terminal acceptor. Membranes were prepared as published (Burnell et al., 1975) and stored at À20 1C until used.
Measurement of mitochondrial CI and CII activity
Reduction of the CII substrate DCPIP in the presence of cells or liver mitochondrial preparations was measured at 600 nm (Trounce et al., 1996) . Reaction mixtures contained 0.5 mM NADH, 5 mM succinate, 10 mM KCN, 50 mM DCPIP and 50 mM PMS. For each assay point, 0.5 mg sample protein was used and a-TOS added as indicated. When measuring the CI (NADH dehydrogenase) activity, PMS was omitted.
RNA interference, cell transfection, western blotting and RT-PCR The siGENOME ON-TARGETplus set of four duplexes of siRNA oligonucleotides (Dharmacon, Chicago, IL, USA) targeting the CybL (SDHC) subunit of CII were used. Nonspecific siRNA was used as a negative control. Transfections of MCF7 cells with siRNA were performed as described (Stapelberg et al., 2005) . B9 cells were transfected using the Topo pCR3.1 Uni plasmid harbouring the CybL gene (Slane et al., 2006) and selected as described (Weber et al., 2003) . Stably transfected and siRNA-treated cells were assessed for SDH activity and SDHC expression. Western blotting was performed as described using anti-SDHC immunoglobulin G (IgG) (clone 3E2; Novus Biologicals, Littleton, CO, USA) with anti-b-actin IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as a loading control. RT-PCR was performed using a standard protocol. The published human CybL (Slane et al., 2006) and Chinese hamster glyceraldehyde 3-phosphate dehydrogenase primers (Sever et al., 2004) were used.
Molecular modelling of a-TOS interaction with UbQ binding in CII For details, see the Supplementary Information.
Animal experiments
Balb/c nu/nu mice were inoculated s.c. with MCF7 cells (2 Â 10 6 cells per mouse). After tumours developed, mice were injected with 10 mmol a-TOS in DMSO i.p. every 3 days. Control mice were injected with an equal volume of DMSO. Tumour size was estimated with digital callipers.
Transgenic FVB/N c-neu mice (Guy et al., 1992) were used with B70% of the female mice developing spontaneous ductal breast carcinomas within B7 months. Tumours were quantified by USI using the Vevo770 device fitted with the RMV704 scan-head (VisualSonics) operated at 60 MHz and with 40 mm resolution Wang et al., 2007) . Mice received 10 mmol a-TOS in corn oil/4% ethanol or the vehicle administered i.p. every 3 days. a-TOS therapy of the animals commenced when the tumour volume was B40 mm 3 . Animal studies were performed according to the guidelines of the Australian and New Zealand Council for the Care and Use of Animals in Research and Teaching and were approved by the local Animal Ethics Committee.
Statistical analyses
Between-group comparisons were made using mean±s.d. and the unpaired Student's t-test. Differences in the mean relative tumour size ( ± s.e.m.) was examined using analyses of covariance (ANCOVA) with days as the covariate. Statistical analyses were performed using SPSS 10.0 analytical software. Statistical significance was accepted at Po0.05.
